Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Computerized electrocardiogram data transformation enables effective algorithmic differentiation of wideQRScomplex tachycardias
Kashou, Anthony H. , LoCoco, Sarah , Shaikh, Preet Ayoub , Katbamna, Bhavesh B., Cooper, Daniel , Sodhi, Sandeep , Cuculich, Phillip S. , Gleva, Marye J. , Deych, Elena , Zhou, Ruiwen , Deshmukh, Abhishek , Asirvatham, Samuel J. , May, Adam M. , Sehrawat, Ojasav , May, Adam M , Asirvatham, Samuel J , Liu, Lei , Noseworthy, Peter A. , DeSimone, Christopher V.

Mayo Clinic

Annals of Noninvasive Electrocardiology | November 21, 2022 | Volume: 28 | Issue: 1 | Pages: No page available

10.1111/anec.13018 | PMID 36409204 Get It

AbstractBackgroundAccurate automated wide QRS complex tachycardia (WCT) differentiation into ventricular tachycardia (VT) and supraventricular wide complex tachycardia (SWCT) can be accomplished using calculations derived from computerized electrocardiogram (ECG) data of paired WCT and baseline ECGs.ObjectiveDevelop and trial novel WCT differentiation approaches for patients with and without a corresponding baseline ECG.MethodsWe developed and trialed WCT differentiation models comprised of novel and previously described parameters derived from WCT and baseline ECG data. In Part 1, a derivation cohort was used to evaluate five different classification models: logistic regression (LR), artificial neural network (ANN), Random Forests [RF], support vector machine (SVM), and ensemble learning (EL). In Part 2, a separate validation cohort was used to prospectively evaluate the performance of two LR models using parameters generated from the WCT ECG alone (Solo Model) and paired WCT and baseline ECGs (Paired Model).ResultsOf the 421 patients of the derivation cohort (Part 1), a favorable area under the receiver operating characteristic curve (AUC) by all modeling subtypes: LR (0.96), ANN (0.96), RF (0.96), SVM (0.96), and EL (0.97). Of the 235 patients of the validation cohort (Part 2), the Solo Model and Paired Model achieved a favorable AUC for 103 patients with (Solo Model 0.87; Paired Model 0.95) and 132 patients without (Solo Model 0.84; Paired Model 0.95) a corroborating electrophysiology procedure or intracardiac device recording.ConclusionAccurate WCT differentiation may be accomplished using computerized data of (i) the WCT ECG alone and (ii) paired WCT and baseline ECGs.
A novel emergency medicine cultural competency curriculum addressing health care disparities
Akhetuamhen, Adesuwa , Ibiebele, Abiye , Leibowitz, Maren K. , Campbell, Mobola , Shakeri, Nahzinine , Bailitz, John , Akhetuamhen, Adesuwa I , Welch, Sarah B

Mayo Clinic

AEM Education and Training | November 21, 2022 | Volume: 6 | Issue: 6 | Pages: No page available

10.1002/aet2.10815 | PMID 36425792 Get It

AbstractBackgroundEffective cultural competency (CC) training for future health professionals is an important first step towards improving healthcare disparities (HCD). The Accreditation Council for Graduate Medical Education (ACGME) now requires that institutions train residents and faculty members in CC relevant to the patient population they serve.MethodsUsing Kern's Model, we created and implemented a novel CC curriculum tailored to specific program needs in an emergency medicine residency program.ResultsAt the end of the curriculum, respondents reported having a better understanding of the importance of CC for their practice (p = 0.004) and of how a patient's personal and historical context affects treatment (p = 0.002). They also reported an increase in the frequency of practicing strategies to reduce bias in themselves (p < 0.001) and others (p < 0.001), as well as comfort interacting with and treating patients from different backgrounds (p < 0.001). Lastly, they reported improved preparedness to collaborate with communities to address HCD (p = 0.004) and to identify community leaders to do so (p < 0.001).ConclusionsThe challenges of CC training demonstrate the need for a standard yet adaptable framework. We have designed, implemented, and evaluated a novel curriculum tailored to the specific needs of our EM residency program. The curriculum improved participants' attitudes, preparedness, and self‐reported behaviors regarding CC and HCD. This framework represents an example of a successful model to meet ACGME requirements.
A Reduced Pancreatic Polypeptide Response is Associated With New-onset Pancreatogenic Diabetes Versus Type 2 Diabetes
Hart, Phil A. , Kudva, Yogish C. , Yadav, Dhiraj , Andersen, Dana K. , Li, Yisheng , Toledo, Frederico G. S. , Wang, Fuchenchu , Cusi, Kenneth , Park, Walter G. , Saeed, Zeb , Considine, Robert V. , Graham, Sarah C., Rinaudo, Jo Ann, Goodarzi, Mark O. , Cusi, Kenneth , Bellin, Melena D. , Bradley, David , Brand, Randall E. , Fisher, William P. , Mather, Kieren J. , Serrano, José

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | November 21, 2022 | Volume: 108 | Issue: 5 | Pages: e120-e128

10.1210/clinem/dgac670 | PMID 36404274 Get It

Abstract Purpose Pancreatogenic diabetes refers to diabetes mellitus (DM) that develops in the setting of a disease of the exocrine pancreas, including pancreatic ductal adenocarcinoma (PDAC) and chronic pancreatitis (CP). We sought to evaluate whether a blunted nutrient response of pancreatic polypeptide (PP) can differentiate these DM subtypes from type 2 DM (T2DM). Methods Subjects with new-onset DM (&lt;3 years’ duration) in the setting of PDAC (PDAC-DM, n = 28), CP (CP-DM, n = 38), or T2DM (n = 99) completed a standardized mixed meal tolerance test, then serum PP concentrations were subsequently measured at a central laboratory. Two-way comparisons of PP concentrations between groups were performed using Wilcoxon rank-sum test and analysis of covariance while adjusting for age, sex, and body mass index. Results The fasting PP concentration was lower in both the PDAC-DM and CP-DM groups than in the T2DM group (P = 0.03 and &lt;0.01, respectively). The fold change in PP at 15 minutes following meal stimulation was significantly lower in the PDAC-DM (median, 1.869) and CP-DM (1.813) groups compared with T2DM (3.283; P &lt; 0.01 for both comparisons). The area under the curve of PP concentration was significantly lower in both the PDAC-DM and CP-DM groups than in T2DM regardless of the interval used for calculation and remained significant after adjustments. Conclusions Fasting PP concentrations and the response to meal stimulation are reduced in new-onset DM associated with PDAC or CP compared with T2DM. These findings support further investigations into the use of PP concentrations to characterize pancreatogenic DM and to understand the pathophysiological role in exocrine pancreatic diseases (NCT03460769).
Tumor necrosis factor‐α inhibitor‐induced morphea and psoriasiform dermatitis in a pediatric patient with Crohn's disease
Reinhart, Jacob P. , Aird, Jenna, Stephens, Michael C., Asch, Sarah , Orandi, Amir B. , Tollefson, Megha M. , Aird, Jenna L., Orandi, Amir B , Reinhart, Jacob

Mayo Clinic

Pediatric Dermatology | November 17, 2022 | Volume: 40 | Issue: 3 | Pages: 519-522

10.1111/pde.15182 | PMID 36385392 Get It

AbstractTumor necrosis factor‐alpha inhibitor therapy for inflammatory bowel disease may be associated with paradoxical cutaneous adverse events, most commonly psoriasiform eruptions. We present the case of a pediatric female patient with Crohn's disease who developed multiple concurrent cutaneous eruptions while on infliximab treatment, including morphea, psoriasiform dermatitis, and genital lichen sclerosus. Although refractory to skin‐directed treatments, all three conditions resolved upon discontinuation of infliximab, supporting their development as a paradoxical reaction to infliximab therapy.
Putting words into action: Adopting vancomycin infusion reaction terminology
Lessard, Sarah , Patel, Lydia, Fung, Brian , Rivera, Christina G. , Zimmermann, Elizabeth, Rivera, Christina G , Zimmermann, Elizabeth

Mayo Clinic

American Journal of Health-System Pharmacy | November 15, 2022 | Volume: 80 | Issue: 4 | Pages: 175-176

10.1093/ajhp/zxac345 | PMID 36377862 Get It

EXTH-20. IDENTIFICATION OF EX VIVO THERAPEUTIC VULNERABILITIES IN DIFFUSE GLIOMAS USING A FUNCTIONAL GENOMICS APPROACH
Lin, Wan‐Hsin , Smadbeck, James B. , Barrett, Michael T. , Feathers, Ryan W. , Sadeghian, Dorsay, Johnson, Sarah H. , Karagouga, Giannoula, Harris, Faye R. , Quiñones‐Hinojosa, Alfredo , Kizilbash, Sani H. , Jaeckle, Kurt A. , Mrugała, Maciej M. , Rosenfeld, Steven S. , Jentoft, Mark E. , Emanuel, Angela, Schaefer-Klein, Janet, Cheville, John C. , Vasmatzis, George , Anastasiadis, Panos Z. , Kizilbash, Sani H , Murphy, Stephen J. , Burns, Terry C. , Bendok, Bernard R. , Moniz‐Garcia, Diogo , Ensign, Shannon P. Fortin , Ida, Cristiane M. , Salomao, Marcela , Yang, Lin , Mansfield, Aaron S. , Borad, Mitesh J.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii213-vii214

10.1093/neuonc/noac209.819 Get It

Abstract Diffuse gliomas are aggressive brain tumors that lack effective therapies. Despite advances in the molecular characterization of gliomas, targeted treatments have failed to improve patient outcomes to date. Here, we employed a functional genomics approach to rapidly identify therapeutic vulnerabilities and provide a strategy to individualize patient treatment. Our process combined comprehensive genomic and transcriptomic tumor profiling, custom algorithms and visualization software for data integration, and preclinical 3-dimensional ex vivo models (mcancers) for drug screening to assess response to therapeutic agents targeting specific molecular alterations. A total of 32 cases, including 5 oligodendrogliomas (1 primary and 4 recurrent), 5 astrocytomas (1 primary and 4 recurrent), and 22 glioblastomas (5 primary and 17 recurrent), were included in the study. Immunohistochemistry and integrated genomics confirmed that mcancers maintain key molecular alterations, including mutations, chromosomal rearrangements and focal amplifications, cellularity, and heterogeneity, faithfully recapitulating the original tumor. A total of 119 single drugs and 183 combinations were tested, including a panel of 26-brain penetrant targeted agents (18 single drugs and 8 combinations) that was curated to target common glioma oncogenic pathways and was tested across all cases. A strong correlation was observed between therapeutic vulnerabilities of glioma mcancers to targeted agents (EGFR, MET, PDGFR, HDAC inhibitors, etc.) and clinical experience. Single agent activity of panel compounds in the ex vivo setting was generally poor, with only 35% mCancers exhibiting &gt; 70% growth inhibition at Cmax. In contrast, combination strategies, especially ones including epigenetic drugs, were significantly more effective (affecting 22 out of 32 mCancers), underscoring the molecular complexity of gliomas and the need for clinical trials testing combination treatments. Our data identified a number of novel combination treatments with significant efficacy across glioma subtypes and molecular profiles, suggesting that our functional genomics pipeline can guide treatment selection and inform clinical trial enrollment for gliomas.
PATH-34. SOLITARY FIBROUS TUMOR: NATURAL HISTORY AND PROGNOSIS IN ACCORDANCE WITH THE WHO 2021 CLASSIFICATION OF CNS TUMORS
Jenkins, Sarah M. , Fritchie, Karen , Moskalev, Evgeny A. , Caron, Alissa, Link, Michael , Brown, Paul D. , Guajardo, Andrew, Wu, Ashely, Louis, David N. , Kaplan, Alexander , Ferrarese, Fabio, Raleigh, David R. , Vega, Jose Velazquez, Alverez, Maria Martinez-Lage, Haller, Florian , Eschbacher, Kathryn L. , Brat, Daniel J. , Santagata, Sandro , Brastianos, Priscilla K. , Alexander, Brian M. , Rossi, Sabrina , Nguyen, Minh, Gross, John , Vega, José E. Velázquez , Rodríguez, Fausto J. , Perry, Arie , Giannini, Caterina

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii157-vii158

10.1093/neuonc/noac209.607 Get It

Abstract Meningeal solitary fibrous tumor (SFT) is a rare tumor with high propensity to recur and metastasize, even late in the course of disease. The WHO 2021 classification of CNS tumors divides SFT in 3 grades, based on mitotic index and necrosis. We re-examined our cohort of 126 patients (57 F, 69 M; mean age 53.0 years) with SFT, confirmed by STAT6 nuclear positivity and/or NAB2::STAT6 fusion, with extended follow-up (median 7.6 years; range 4 days-26.6 years). Tumors included 76 grade 1, 36 grade 2 and 14 grade 3 according to 2021 WHO criteria, evaluated at primary resection (n=90), recurrence (n=35), or metastasis (n=1). Fifty-six patients had one or more post-surgical events, the earliest event being local recurrence (n=41) or metastasis (n=15). Forty patients died (29 of disease; 9 of other causes; 2 unknown). Overall survival (OS), and progression-free survival (PFS, recurrence and/or metastasis) from time of primary resection (n=90) were not significantly associated with grade; however, risk of metastasis differed significantly (5-year estimates: 4.1%, 15.3%, and 37.8% for grades 1, 2, and 3 SFT, respectively; p=0.005). NAB2::STAT6 fusion status was known in 101 cases (51 = ex5-7-ex16-17, 26 = ex4_ex2-3; 12 = ex2-3_exANY/other and 12 =no fusion). Disease specific 5-year survival in primary tumors with molecular data (n = 75) was 80.0% in patients whose tumors harbored ex5-7_ex16-17 compared to 93.3% in all others combined (p=0.014). Targeted TERT promoter mutation testing was performed in 98 patients, revealing patients with tumors lacking TERT promoter mutation (n = 88) were younger at time of surgery than those harboring a mutation (n=10; p = 0.022), and none with a mutation harboring concurrent ex5-7_ex16-17 fusion (p = 0.0009). In summary, WHO 2021 grade is associated with risk of metastasis. Patients whose tumors harbor ex5-7_ex16-17 fusion have a higher risk of dying from the disease.
PATH-36. GENOMIC MARKERS OF RECURRENCE RISK IN ATYPICAL MENINGIOMA FOLLOWING GROSS TOTAL RESECTION
Weiskittel, Taylor M. , Jenkins, Sarah M. , Dasari, Surendra , Uhm, Joon H. , Kipp, Benjamin R. , Sukov, William R. , Vaubel, Rachael A. , Kumar, Rahul , Lachance, Daniel Honore , Brown, Paul, Gompel, Jamie J. Van , Giannini, Caterina , Johnson, Derek R. , Raghunathan, Aditya

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii158-vii158

10.1093/neuonc/noac209.609 Get It

Abstract Atypical meningiomas (CNS WHO grade 2) show an intermediate risk of recurrence/progression, and molecular parameters informing management following gross total resection (GTR) remain to be established. We performed comprehensive genomic analysis in 63 patients who underwent GTR of an atypical meningioma. Median age was 59.8 years, 41 patients (65.1%) were female, and 8/62 patients (12.9%) underwent radiation therapy following resection. Follow-up was available for all patients (median 10 years), with recurrence/progression in 17 (5-year PFS: 84.2%; 10-year PFS: 71.0%). Tumors were evaluated by next generation sequencing (n=61), chromosomal microarray (n=63), DNA methylation profiling (n=62), and H3K27me3 immunohistochemistry (n=62). Next generation sequencing using a CLIA-certified 50-gene Neuro-Oncology specific panel identified pathogenic alterations in NF2 (n=31; 50.8%), SMARCB1 (n=5; 8.2%), AKT1 (n=2; 3.3%), TERT (n=1, 1.6%), SMO (n=1), SUFU (n=1), TP53 (n=1), and PTEN (n=1). There was trend toward decreased PFS in patients with NF2 alterations (p=0.078) which was not statistically significant. Copy number variants (CNVs) were identified using OncoScan (ThermoFisher). The most frequent CNVs were loss -22 (n=45; 71.4%), -1p (n=30, 47.6%), -14 (n=21, 33.3%), -6q (n=18, 28.6%), -10q (n=15, 23.8%), -X (n=13, 20.6%), and -18 (n=11, 17.4%). CNVs associated with decreased PFS included -1p (p=0.015), -7p (p=0.007), -10q (p=0.0007), and -18 (p=0.0376). DNA methylation profiling was performed using the Illumina MethylationEPIC array (n=62) and evaluated using the DKFZ classifier (v12.3). Based on the highest score, tumors matched to benign (n=32; 51.6%) or intermediate (n=29; 46.7%) meningioma subclasses or showed non-contributory profiles (n=1; 1.6%). Methylation class (benign vs. intermediate) showed no association with PFS (p=0.96). H3K27 trimethylation (H3K27me3) was unequivocally lost in 4 (6.5%) tumors, which was insufficient for PFS analysis. Overall, our study supports CNV profiling of atypical meningiomas following GTR, which can be implemented using existing, clinically validated technologies. Molecular predictors could guide use of radiotherapy in these patients.
NIMG-12. DSC-MRI PERFUSION IMAGING IN UNTREATED BRAIN METASTASES USING THE CONSENSUS ACQUISITION PROTOCOL: A MULTI-SITE BENCHMARK STUDY
Kohn, Sarah, Kong, Min J. , Phung, Daniel , Urcuyo, Javier , Ye, Jason, Attenello, Frank, Mendoza, Jesse, Shiroishi, Mark S. , Hu, Leland , Kohn, Sarah, Prah, Melissa A. , Ye, Jason C. , Schmainda, Kathleen M

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii163-vii164

10.1093/neuonc/noac209.630 Get It

Abstract INTRODUCTION DSC-MRI perfusion methods are commonly used to evaluate both primary and metastatic brain cancer with the creation of maps of relative cerebral blood volume (rCBV). Recently, guidelines were established to ensure a standard DSC-MRI acquisition protocol that reduces inter-site variability. The purpose of this study was to initiate the determination of rCBV benchmark values using the DSC-MRI consensus protocol in treatment-naïve brain metastases. METHODS Patients from three sites with treatment-naïve, contrast-enhancing brain metastases on MRI were considered for inclusion in this retrospective study. The MRIs included pre- and post-contrast T1w(T1+C) images obtained after administration of gadolinium-based contrast agent (GBCA) (0.1 mmol/kg), which serves as the recommended preload for the DSC-MRI data collection. A 2nd GBCA dose (0.1 mmol/kg) was administered 40-60sec after the collection of baseline GRE-EPI images using recommended settings (FA=60o, TE/TR=30ms/1100-1250ms) for 120s. Calibrated pre/post T1w difference maps (dT1) were used for delineation of enhancing lesion, and standardized (calibrated) rCBV (sRCBV) created. Mean sRCBV for metastases were compared to normal appearing white matter (NAWM) and treatment-naive glioblastoma (GBM) from a previous study. Pairwise comparisons were performed using the Mann-Whitney nonparametric test. RESULTS N=52 patients with primary histology of lung (n=27); breast (n=6); skin (n=7); gastrointestinal (GI: n=3) and genitourinary (GU: n=9) cancers were included in comparison to GBM (n=31). The mean sRCBV for all metastases (1.77+/-1.05) is significantly lower (p=0.0003) than for GBM (2.67+/-1.34) but with both statistically greater (p&lt; 0.0001) than NAWM (0.706+/-0.163). Individually, lung (1.47+/- 0.61), breast (2.275+/-0.87), skin (2.10+/-1.22), GI (1.91+/- 0.64) and GU (2.01+/-0.63) mean sRCBV are statistically greater than for NAWM. CONCLUSION Using the consensus DSC-MRI acquisition protocol confirms use of sRCBV to identify biologically active, treatment-naive brain metastases setting benchmark values for future applications.
Response to Letter to the Editor Regarding “Delphi Method Consensus on Priority Global Otolaryngology–Head and Neck Surgery Conditions and Procedures”
Nuss, Sarah , Patterson, Rolvix H. , Wiedermann, Josh, Cahill, Gabrielle , Alkire, Blake C., Okerosi, Samuel , Xu, Mary Jue , Patterson, Rolvix H

Mayo Clinic

Otolaryngology–Head and Neck Surgery | November 12, 2022 | Volume: 168 | Issue: 2 | Pages: 249-250

10.1177/01945998221095101 | PMID 36373366 Get It